Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 131
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Brain Behav Immun ; 107: 330-344, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-36371010

RESUMEN

BACKGROUND: Stroke is a major cause of morbidity and mortality worldwide. After cerebral ischemia, peripheral immune cells infiltrate the brain and elicit an inflammatory response. However, it is not clear when and how these peripheral immune cells affect the central inflammatory response, and whether interventions that target these processes can alleviate ischemia-reperfusion (I/R) injury. METHODS: Single-cell transcriptomic sequencing and bioinformatics analysis were performed on peripheral blood of mice at different times after I/R to analyze the key molecule of cell subsets. Then, the expression pattern of this molecule was determined through various biological experiments, including quantitative RT-PCR, western blot, ELISA, and in situ hybridization. Next, the function of this molecule was assessed using knockout mice and the corresponding inhibitor. RESULTS: Single-cell transcriptomic sequencing revealed that peripheral monocyte subpopulations increased significantly after I/R. Cathepsin S (Ctss)was identified as a key molecule regulating monocyte activation by pseudotime trajectory analysis and gene function analysis. Next, Cathepsin S was confirmed to be expressed in monocytes with the highest expression level 3 days after I/R. Infarct size (p < 0.05), neurological function scores (p < 0.05), and apoptosis and vascular leakage rates were significantly reduced after Ctss knockout. In addition, CTSS destroyed the blood-brain barrier (BBB) by binding to junctional adhesion molecule (JAM) family proteins to cause their degradation. CONCLUSIONS: Cathepsin S inhibition attenuated cerebral I/R injury; therefore, cathepsin S can be used as a novel target for drug intervention after stroke.


Asunto(s)
Daño por Reperfusión , Accidente Cerebrovascular , Animales , Ratones , Monocitos , Catepsinas , Daño por Reperfusión/genética , Análisis de Secuencia de ARN
2.
Mol Psychiatry ; 27(10): 4297-4306, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35840796

RESUMEN

Mendelian-randomization (MR) studies using large-scale genome-wide association studies (GWAS) have identified causal association between educational attainment and Alzheimer's disease (AD). However, the underlying mechanisms are still required to be explored. Here, we conduct univariable and multivariable MR analyses using large-scale educational attainment, cognitive performance, intelligence and AD GWAS datasets. In stage 1, we found significant causal effects of educational attainment on cognitive performance (beta = 0.907, 95% confidence interval (CI): 0.884-0.930, P < 1.145E-299), and vice versa (beta = 0.571, 95% CI: 0.557-0.585, P < 1.145E-299). In stage 2, we found that both increase in educational attainment (odds ratio (OR) = 0.72, 95% CI: 0.66-0.78, P = 1.39E-14) and cognitive performance (OR = 0.69, 95% CI: 0.64-0.75, P = 1.78E-20) could reduce the risk of AD. In stage 3, we found that educational attainment may protect against AD dependently of cognitive performance (OR = 1.07, 95% CI: 0.90-1.28, P = 4.48E-01), and cognitive performance may protect against AD independently of educational attainment (OR = 0.69, 95% CI: 0.53-0.89, P = 5.00E-03). In stage 4, we found significant causal effects of cognitive performance on intelligence (beta = 0.907, 95% CI: 0.877-0.938, P < 1.145E-299), and vice versa (beta = 0.957, 95% CI: 0.937-0.978, P < 1.145E-299). In stage 5, we identified that cognitive performance may protect against AD independently of intelligence (OR = 0.74, 95% CI: 0.61-0.90, P = 2.00E-03), and intelligence may protect against AD dependently of cognitive performance (OR = 1.17, 95% CI: 0.40-3.43, P = 4.48E-01). Collectively, our univariable and multivariable MR analyses highlight the protective role of cognitive performance in AD independently of educational attainment and intelligence. In addition to the intelligence, we extend the mechanisms underlying the associations of educational attainment with AD.


Asunto(s)
Enfermedad de Alzheimer , Estudio de Asociación del Genoma Completo , Humanos , Enfermedad de Alzheimer/genética , Polimorfismo de Nucleótido Simple , Inteligencia , Escolaridad , Cognición
3.
Analyst ; 148(13): 3028-3035, 2023 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-37265383

RESUMEN

Low back pain (LBP) seriously endangers human health and quality of life, and the detection of thoracolumbar fasciitis (TLF) is vital for the prevention and treatment of LBP. Surface-enhanced Raman scattering (SERS) is considered as a powerful technique for fingerprint detection due to the inherent richness of the spectral data. In this work, a novel SERS strategy based on a three-dimensional substrate was developed for fingerprint analysis for early diagnosis of TLF. A rat TLF model was established and the model was evaluated from the immunological and behavioral perspectives. Vibrational fingerprints were obtained by SERS testing of isolated fascial tissue and were used to explore the material changes during fasciitis. SERS spectra were analyzed using principal component analysis (PCA) that allowed unambiguous distinction and monitoring of component changes during TLF. Furthermore, in order to further clarify the occurrence and development of TLF, we combined clinical samples for analysis, and investigated the inflammatory factor expression levels of CRP and SAA in TLF. Our results demonstrated that tryptophan, phenylalanine and glycogen could unambiguously distinguish TLF as confirmed by SERS analysis, a method that is capable of noninvasive characterization of and diagnosis of TLF during LBP. We have provided a new tool that may promote in-depth study of the mechanism and treatment of fasciitis.


Asunto(s)
Dolor de la Región Lumbar , Espectrometría Raman/métodos , Dolor de la Región Lumbar/diagnóstico , Masculino , Animales , Ratas
4.
BMC Med ; 19(1): 11, 2021 01 19.
Artículo en Inglés | MEDLINE | ID: mdl-33461566

RESUMEN

BACKGROUND: It has been well established that the TMEM106B gene rs1990622 variant was a frontotemporal dementia (FTD) risk factor. Until recently, growing evidence highlights the role of TMEM106B in Alzheimer's disease (AD). However, it remains largely unclear about the role of rs1990622 variant in AD. METHODS: Here, we conducted comprehensive analyses including genetic association study, gene expression analysis, eQTLs analysis, and colocalization analysis. In stage 1, we conducted a genetic association analysis of rs1990622 using large-scale genome-wide association study (GWAS) datasets from International Genomics of Alzheimer's Project (21,982 AD and 41,944 cognitively normal controls) and UK Biobank (314,278 participants). In stage 2, we performed a gene expression analysis of TMEM106B in 49 different human tissues using the gene expression data in GTEx. In stage 3, we performed an expression quantitative trait loci (eQTLs) analysis using multiple datasets from UKBEC, GTEx, and Mayo RNAseq Study. In stage 4, we performed a colocalization analysis to provide evidence of the AD GWAS and eQTLs pair influencing both AD and the TMEM106B expression at a particular region. RESULTS: We found (1) rs1990622 variant T allele contributed to AD risk. A sex-specific analysis in UK Biobank further indicated that rs1990622 T allele only contributed to increased AD risk in females, but not in males; (2) TMEM106B showed different expression in different human brain tissues especially high expression in cerebellum; (3) rs1990622 variant could regulate the expression of TMEM106B in human brain tissues, which vary considerably in different disease statuses, the mean ages at death, the percents of females, and the different descents of the selected donors; (4) colocalization analysis provided suggestive evidence that the same variant contributed to AD risk and TMEM106B expression in cerebellum. CONCLUSION: Our comprehensive analyses highlighted the role of FTD rs1990622 variant in AD risk. This cross-disease approach may delineate disease-specific and common features, which will be important for both diagnostic and therapeutic development purposes. Meanwhile, these findings highlight the importance to better understand TMEM106B function and dysfunction in the context of normal aging and neurodegenerative diseases.


Asunto(s)
Enfermedad de Alzheimer/genética , Encéfalo/metabolismo , Variación Genética , Proteínas de la Membrana/genética , Proteínas del Tejido Nervioso/genética , Alelos , Enfermedad de Alzheimer/metabolismo , Cognición , Femenino , Regulación de la Expresión Génica , Estudio de Asociación del Genoma Completo , Humanos , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Factores Sexuales
5.
Neurochem Res ; 46(5): 1112-1118, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-33555527

RESUMEN

Immune response plays a vital role in the pathogenesis of neuropathic pain. Immune response-targeted therapy becomes an effective strategy for treating neuropathic pain. Licochalcone A (Lic-A) possesses anti-inflammatory and neuroprotective effects. However, the potential of Lic-A to attenuate neuropathic pain has not been well explored. To investigate the protective effect and evaluate the underlying mechanism of Lic-A against neuropathic pain in a rat model. Chronic constriction injury (CCI) surgery was employed in rats to establish neuropathic pain model. Rats were intraperitoneally administrated with Lic-A (1.25, 2.50 and 5.00 mg/kg) twice daily. Mechanical withdrawal threshold and thermal withdrawal latency were used to evaluate neuropathic pain. After administration, the lumbar spinal cord enlargement of rats was collected for ELISA, Western blot and immunofluorescence analysis. Mechanical withdrawal threshold and thermal withdrawal latency results showed that Lic-A significantly attenuated CCI-evoked neuropathic pain in dose-dependent manner. Lic-A administration also effectively blocked microglia activation. Moreover, Lic-A suppressed p38 phosphorylation and the release of inflammatory factors such as tumor necrosis factor-α, interleukin-1 and interleukin-6. Our findings provide evidence that Lic-A may have the potential to attenuate CCI-evoked neuropathic pain in rats by inhibiting microglia activation and inflammatory response.


Asunto(s)
Chalconas/uso terapéutico , Inflamación/tratamiento farmacológico , Microglía/efectos de los fármacos , Neuralgia/tratamiento farmacológico , Animales , Proteínas de Unión al Calcio/metabolismo , Enfermedad Crónica/tratamiento farmacológico , Constricción Patológica , Inflamación/complicaciones , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Masculino , Proteínas de Microfilamentos/metabolismo , Neuralgia/complicaciones , Fosforilación/efectos de los fármacos , Ratas Sprague-Dawley , Nervio Ciático/lesiones , Asta Dorsal de la Médula Espinal/efectos de los fármacos , Asta Dorsal de la Médula Espinal/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
6.
J Nanobiotechnology ; 19(1): 98, 2021 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-33827604

RESUMEN

BACKGROUND: Nano-Fenton reactors as novel strategy to selectively convert hydrogen peroxide (H2O2) into active hydroxyl radicals in tumor microenvironment for cancer therapy had attracted much attention. However, side effects and low efficiency remain the main drawbacks for cancer precise therapy. RESULTS: Here, ruthenium-loaded palmitoyl ascorbate (PA)-modified mesoporous silica (Ru@SiO2-PA) was successfully fabricated and characterized. The results indicated that Ru@SiO2-PA under pH6.0 environment displayed enhanced growth inhibition against human cancer cells than that of pH7.4, which indicated the super selectivity between cancer cells and normal cells. Ru@SiO2-PA also induced enhanced cancer cells apoptosis, followed by caspase-3 activation and cytochrome-c release. Mechanism investigation revealed that Ru@SiO2-PA caused enhanced generation of superoxide anion, which subsequently triggered DNA damage and dysfunction of MAPKs and PI3K/AKT pathways. Moreover, Ru@SiO2-PA effectively inhibited tumor spheroids and tumor xenografts growth in vivo by induction of apoptosis. The real-time imaging by monitoring Ru fluorescence in vitro and in vivo revealed that Ru@SiO2-PA mainly accumulated in cell nucleus and tumor xenografts. Importantly, Ru@SiO2-PA showed no side effects in vivo, predicting the safety and potential application in clinic. CONCLUSIONS: Our findings validated the rational design that Ru@SiO2-PA can act as novel tumor microenvironment-response nano-Fenton reactors for cancer precise therapy.


Asunto(s)
Rutenio/química , Dióxido de Silicio/química , Dióxido de Silicio/farmacología , Microambiente Tumoral/efectos de los fármacos , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Daño del ADN/efectos de los fármacos , Humanos , Peróxido de Hidrógeno , Ratones , Ratones Desnudos , Nanopartículas/química , Nanopartículas/uso terapéutico , Fosfatidilinositol 3-Quinasas , Ensayos Antitumor por Modelo de Xenoinjerto
7.
Mikrochim Acta ; 188(12): 428, 2021 11 23.
Artículo en Inglés | MEDLINE | ID: mdl-34816331

RESUMEN

A surface-enhanced Raman scattering (SERS)-based immunoassay with gold nanostars (GNSs) is utilized for determination of the subarachnoid hemorrhage (SAH) biomarker glial fibrillary acidic protein (GFAP) at very low concentration levels, which allows for early diagnosis and guides clinical decision-making to treat SAH-induced complications. The Raman reporter 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) modified on GNSs was selected as the SERS tags. The SERS immunoassay was assembled by SERS tag and GFAP probe-immobilized ITO substrate. Therefore, the level of GFAP can be detected by monitoring the characteristic Raman peak intensity of GFAP-conjugated GNSs at 1332 cm-1 with a very low detection limit. Under optimized conditions, the assay can work in the GFAP concentration range from 1 pg⋅mL-1 to 1 µg⋅mL-1, with a detection limit as low as 0.54 fg⋅mL-1. The performance of the SERS immunoassay proven by the detection of GFAP is equivalent to that of the conventional enzyme-linked immunosorbent assay (ELISA). Scheme 1. Schematic illustration of GNSs SERS immunoassay for ultrasensitive dynamic change detection of GFAP. (SAH: Subarachnoid hemorrhage, SCF: Cerebrospinal fluid; GNSs: gold nanostars; SERS: surface-enhanced Raman scattering; GFAP: glial fibrillary acidic protein).


Asunto(s)
Técnicas Biosensibles/métodos , Proteína Ácida Fibrilar de la Glía/metabolismo , Oro/química , Inmunoensayo/métodos , Espectrometría Raman/métodos , Ensayo de Inmunoadsorción Enzimática , Humanos
8.
J Cell Mol Med ; 23(3): 2268-2271, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30637964

RESUMEN

Until recently, randomized controlled trials have not demonstrated convincing evidence that vitamin D, or vitamin D in combination with calcium supplementation could improve bone mineral density (BMD), osteoporosis and fracture. It remains unclear whether vitamin D levels are causally associated with total body BMD. Here, we performed a Mendelian randomization study to investigate the association of vitamin D levels with total body BMD using a large-scale vitamin D genome-wide association study (GWAS) dataset (including 79 366 individuals) and a large-scale total body BMD GWAS dataset (including 66,628 individuals). We selected three Mendelian randomization methods including inverse-variance weighted meta-analysis (IVW), weighted median regression and MR-Egger regression. All these three methods did not show statistically significant association of genetically increased vitamin D levels with total body BMD. Importantly, our findings are consistent with recent randomized clinical trials and Mendelian randomization study. In summary, we provide genetic evidence that increased vitamin D levels could not improve BMD in the general population. Hence, vitamin D supplementation alone may not be associated with reduced fracture incidence among community-dwelling adults without known vitamin D deficiency, osteoporosis, or prior fracture.


Asunto(s)
Densidad Ósea/genética , Predisposición Genética a la Enfermedad/genética , Análisis de la Aleatorización Mendeliana/métodos , Osteoporosis/genética , Polimorfismo de Nucleótido Simple , Vitamina D/sangre , Adolescente , Adulto , Anciano , Calcio/administración & dosificación , Suplementos Dietéticos , Femenino , Fracturas Óseas/clasificación , Fracturas Óseas/genética , Estudio de Asociación del Genoma Completo/métodos , Humanos , Masculino , Persona de Mediana Edad , Osteoporosis/sangre , Vitamina D/administración & dosificación
9.
Mikrochim Acta ; 186(8): 548, 2019 07 18.
Artículo en Inglés | MEDLINE | ID: mdl-31321545

RESUMEN

A surface-enhanced Raman scattering (SERS)-based lateral flow assay (LFA) is described for the quantitative analysis of the proteinic stroke biomarker S100-ß that has to be detected at very low concentration levels. The Raman reporter 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) on gold nanoparticles (GNPs) was employed as the SERS tags. They are shown to perform much better than bare GNPs in LF strips. The S100-ß protein can be detected by this method with very low detection limits by monitoring the intensity of the characteristic Raman peak of the S100-ß protein-conjugated GNPs at 1332 cm-1. Under optimized conditions, the assay works in the 1 pg·mL-1 to 40 ng·mL-1 S100-ß concentration range, and the detection limit is as low as 0.14 pg·mL-1. This is lower by a factor of 3 compared to colorimetric or fluorimetric methods. Graphical abstract Schematic illustration of the configuration (A) and the principle of the SERS-based lateral flow assay for quantification of S100-ß (B).


Asunto(s)
Técnicas Biosensibles , Subunidad beta de la Proteína de Unión al Calcio S100/análisis , Bioensayo , Biomarcadores/análisis , Oro/química , Límite de Detección , Nanopartículas del Metal/química , Espectrometría Raman , Accidente Cerebrovascular
10.
Med Sci Monit ; 24: 8860-8869, 2018 Dec 07.
Artículo en Inglés | MEDLINE | ID: mdl-30531687

RESUMEN

BACKGROUND Intranasal calcitonin gene-related peptide (CGRP) delivery offers a noninvasive method of bypassing the blood-brain barrier for the delivery of CGRP to the brain. Here, we first reported the therapeutic benefits of intranasal CGRP delivery in rats following middle cerebral artery occlusion (MCAO). MATERIAL AND METHODS Real-time quantitative polymerase chain reaction (RT-qPCR) assay, enzyme-linked immunosorbent assay (ELISA), rat MCAO model, TTC (2, 3, 5-triphenyltetrazolium chloride) staining, hematoxylin and eosin (H & E) staining, Morris water maze test, TUNEL assay, immunofluorescence, and western blot assay were used to investigate the role of CGRP in rats. Cell Counting Kit-8 assay, colony formation assay, cell cycle assay, apoptosis assay, western blot assay, and TOP/FOP assay were used to investigate the role of CGRP in normal human astrocytes (NHA) cells. RESULTS The CGRP-MCAO-NDDS (nasal drug delivery system) group showed a significant reduction in the infarct volume and improvement in neurologic deficit tests of motor, sensory, reflex and vestibulo-motor functions compared to those rats in the CGRP-MCAO-IV group. CGRP markedly inhibited apoptosis and increased the expression of vascular endothelial growth factor (VEGF) and bFGF and decreased the expression of GAP43 in the cortex of MCAO rats. CGRP promoted cell proliferation and cell cycle process and inhibited cell apoptosis through the Wnt/ß-catenin pathway in NHA cells. CONCLUSIONS This noninvasive, simple, and cost-effective method is a potential treatment strategy for focal cerebral ischemic injury.


Asunto(s)
Isquemia Encefálica/terapia , Péptido Relacionado con Gen de Calcitonina/metabolismo , Péptido Relacionado con Gen de Calcitonina/uso terapéutico , Administración Intranasal/métodos , Animales , Barrera Hematoencefálica/efectos de los fármacos , Encéfalo/metabolismo , Lesiones Encefálicas/tratamiento farmacológico , Calcitonina/metabolismo , Péptido Relacionado con Gen de Calcitonina/administración & dosificación , Arterias Cerebrales , Modelos Animales de Enfermedad , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Isquemia/tratamiento farmacológico , Masculino , Fármacos Neuroprotectores/farmacología , Ratas , Ratas Wistar , Daño por Reperfusión/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Vía de Señalización Wnt/efectos de los fármacos , beta Catenina/efectos de los fármacos
11.
J Nanosci Nanotechnol ; 18(10): 6971-6977, 2018 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-29954518

RESUMEN

The composite catalysts of CeO2/multi-walled carbon nanotubes (CNTs)-Pt/CNTs were prepared. Morphologies of the resulting catalysts were characterized by transmission electron microscopy (TEM) and X-ray diffraction (XRD) techniques. The results indicated that most of particles have a narrow particle size distribution, and the size distribution followed the Gaussian distribution. The electro-catalytic activity of the CeO2 or CeO2/CNTs modified Pt/CNTs catalysts towards the methanol oxidation reaction was examined by using the cyclic voltammetry (CV) experiments in H2SO4 containing methanol electrolyte. It is found that both catalysts of CeO2-Pt/CNTs and CeO2/CNTs-Pt/CNTs exhibited significantly improved electrochemically active surface area (EAS) and high catalytic activity toward methanol electro-oxidation, as compared with Pt/CNTs. Furthermore, the corresponding CO-stripping test showed that the onset potential and peak maxima in ceria incorporated platinum catalyst were shifted to lower potentials compared to that of the ceria free platinum system. The effects of the loading of CeO2 on CNTs on the electrocatalytic activity of the composite catalysts for methanol oxidation were investigated. We found that the optimal value of ceria loading on CNTs occurred at 40%.

12.
J Craniofac Surg ; 29(7): 1689-1692, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30234712

RESUMEN

Many studies have reported the recovery ability of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for neural diseases. In this study, the authors explored the roles of UC-MSCs to treat the traumatic brain injury. Umbilical cord-derived mesenchymal stem cells were isolated from healthy neonatal rat umbilical cord immediately after delivery. The traumatic brain injury (TBI) model was formed by the classical gravity method. The authors detected the behavior changes and measured the levels of inflammatory factors, such as interleukin-lß and tumor necrosis factor-α by enzyme linked immunosorbent assay (ELISA) at 1, 2, 3, 4 weeks after transplantation between TBI treated and untreated with UC-MSCs. Simultaneously, the expression of glial cell line-derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) were measured by real-time-polymerase chain reaction and ELISA.The authors found that the group of transplantation UC-MSCs has a significant improvement than other group treated by phosphate buffered saline. In the behavioral test, the Neurological Severity Scores of UC-MSCs + TBI group were lower than TBI group (P < 0.05), but not obviously higher than control group at 2, 3, and 4week, respectively. The inflammatory factors are significantly reduced comparison with TBI group (P < 0.05), but both GDNF and BDNF were higher than TBI group (P < 0.05). The results indicated that UC-MSCs might play an important role in TBI recovery through inhibiting the release of inflammatory factors and increasing the expression of GDNF and BDNF.


Asunto(s)
Lesiones Traumáticas del Encéfalo/terapia , Trasplante de Células Madre Mesenquimatosas , Cordón Umbilical/citología , Animales , Conducta Animal , Lesiones Traumáticas del Encéfalo/metabolismo , Factor Neurotrófico Derivado del Encéfalo/genética , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Factor Neurotrófico Derivado de la Línea Celular Glial/genética , Factor Neurotrófico Derivado de la Línea Celular Glial/metabolismo , Interleucina-1beta/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley , Factor de Necrosis Tumoral alfa/metabolismo
13.
J Stroke Cerebrovasc Dis ; 27(8): 2228-2234, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29759940

RESUMEN

PURPOSE: This study aimed to investigate the correlation between cerebral microbleeds and carotid atherosclerosis in patients with ischemic stroke. SUBJECTS AND METHODS: Patients with ischemic stroke treated in a hospital in China from 2016 to 2017 were enrolled in the study. Based on the results from susceptibility-weighted imaging, the patients were divided into cerebral microbleed and noncerebral microbleed groups. The degree of carotid atherosclerosis was assessed with carotid intima-media thickness (CIMB) and Crouse score of carotid plaque. The details of patients' demographic information, cerebrovascular disease-related risk factors, carotid atherosclerosis indices, cerebral microbleed distribution, and grading were recorded, compared, and analyzed. RESULTS: Logistic regression analysis of the 198 patients showed that CIMB and Crouse score were significantly correlated with the occurrence of cerebral microbleeds. The CIMB thickening group (P = .03) and the plaque group (P = .01) were more susceptible to cerebral microbleeds. In the distribution of cerebral microbleed sites, Crouse scores were the highest in the mixed group and showed a statistically significant difference (P < .01). As the degree of carotid atherosclerosis increased, the average number of cerebral microbleeds also increased (P < .01). The receiver operating characteristic curve analysis of the carotid atherosclerosis indices showed a statistically significant difference. The CIMB value combined with the Crouse score was the best indicator (P < .01). CONCLUSION: In patients with ischemic stroke, cerebral microbleeds are closely related to carotid atherosclerosis. Active control of carotid atherosclerosis is important to prevent cerebral microbleeds in patients with ischemic stroke.


Asunto(s)
Isquemia Encefálica/complicaciones , Enfermedades de las Arterias Carótidas/complicaciones , Hemorragia Cerebral/complicaciones , Placa Aterosclerótica/complicaciones , Accidente Cerebrovascular/complicaciones , Anciano , Anciano de 80 o más Años , Isquemia Encefálica/diagnóstico por imagen , Isquemia Encefálica/epidemiología , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Enfermedades de las Arterias Carótidas/epidemiología , Grosor Intima-Media Carotídeo , Hemorragia Cerebral/diagnóstico por imagen , Hemorragia Cerebral/epidemiología , Femenino , Humanos , Modelos Logísticos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Placa Aterosclerótica/diagnóstico por imagen , Placa Aterosclerótica/epidemiología , Curva ROC , Factores de Riesgo , Índice de Severidad de la Enfermedad , Accidente Cerebrovascular/diagnóstico por imagen , Accidente Cerebrovascular/epidemiología , Ultrasonografía Doppler
14.
Cell Mol Neurobiol ; 37(5): 919-929, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27678140

RESUMEN

The CD4+CD25+ regulatory T cells (Tregs), an innate immunomodulator, suppress cerebral inflammation and maintain immune homeostasis in multiple central nervous system injury, but its role in intracerebral hemorrhage (ICH) has not been fully characterized. This study investigated the effect of Tregs on brain injury using the mouse ICH model, which is established by autologous blood infusion. The results showed that tail intravenous injection of Tregs significantly reduced brain water content and Evans blue dye extravasation of perihematoma at day (1, 3 and 7), and improved short- and long-term neurological deficits following ICH in mouse model. Tregs treatment reduced the content of pro-inflammatory cytokines interleukin (IL)-1ß, IL-6, tumor necrosis factor-α, and malondialdehyde, while increasing the superoxide dismutase (SOD) enzymatic activity at day (1, 3 and 7) following ICH. Furthermore, Tregs treatment obviously reduced the number of NF-κB+, IL-6+, TUNEL+ and active caspase-3+ cells at day 3 after ICH. These results indicate that adoptive transfer of Tregs may provide neuroprotection following ICH in mouse models.


Asunto(s)
Traslado Adoptivo , Hemorragia Cerebral/inmunología , Hemorragia Cerebral/terapia , Hematoma/inmunología , Hematoma/terapia , Inflamación/patología , Linfocitos T Reguladores/inmunología , Animales , Apoptosis , Barrera Hematoencefálica/patología , Hemorragia Cerebral/patología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Hematoma/complicaciones , Hematoma/patología , Masculino , Malondialdehído/metabolismo , Ratones Endogámicos C57BL , Superóxido Dismutasa/metabolismo , Factor de Transcripción ReIA/metabolismo
15.
Cell Mol Neurobiol ; 37(2): 211-222, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26971524

RESUMEN

Progressive accumulation of beta-amyloid (Aß) will form the senile plaques and cause oxidative damage and neuronal cell death, which was accepted as the major pathological mechanism to the Alzheimer's disease (AD). Hence, inhibition of Aß-induced oxidative damage and neuronal cell apoptosis by agents with potential antioxidant properties represents one of the most effective strategies in combating human AD. Curcumin (Cur) a natural extraction from curcuma longa has potential of pharmacological efficacy, including the benefit to antagonize Aß-induced neurotoxicity. However, the molecular mechanism remains elusive. The present study evaluated the protective effect of Cur against Aß-induced cytotoxicity and apoptosis in PC12 cells and investigated the underlying mechanism. The results showed that Cur markedly reduced Aß-induced cytotoxicity by inhibition of mitochondria-mediated apoptosis through regulation of Bcl-2 family. The PARP cleavage, caspases activation, and ROS-mediated DNA damage induced by Aß were all significantly blocked by Cur. Moreover, regulation of p38 MAPK and AKT pathways both contributed to this protective potency. Our findings suggested that Cur could effectively suppress Aß-induced cytotoxicity and apoptosis by inhibition of ROS-mediated oxidative damage and regulation of ERK pathway, which validated its therapeutic potential in chemoprevention and chemotherapy of Aß-induced neurotoxicity.


Asunto(s)
Péptidos beta-Amiloides/toxicidad , Curcumina/farmacología , Sistema de Señalización de MAP Quinasas/fisiología , Fragmentos de Péptidos/toxicidad , Especies Reactivas de Oxígeno/metabolismo , Animales , Antiinflamatorios no Esteroideos/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Relación Dosis-Respuesta a Droga , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Células PC12 , Ratas , Especies Reactivas de Oxígeno/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología
16.
Neurochem Res ; 42(2): 541-551, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27868153

RESUMEN

Carnosine, an endogenous dipeptide (ß-alanyl-L-histidine), exerts multiple neuroprotective properties, but its role in intracerebral hemorrhage (ICH) remains unclear. This study investigates the effect of Carnosine on brain injury using the rat ICH model, which is established by type IV collagenase caudatum infusion. The results indicate that intraperitoneal administration of Carnosine (1000 mg/kg) significantly attenuates brain edema, blood-brain barrier (BBB) disruption, oxidative stress, microglia activation and neuronal apoptosis of perihematoma at 72 h following ICH in rats models, as convinced by preventing the disruption of tight junction protein ZO-1, occludin and claudin-5, followed by the decrease of ROS, MDA, 3-NT, 8-OHDG level and the increase of GSH-Px and SOD activity, then followed by the decline of Iba-1, ED-1, active caspase-3 and TUNEL positive cells and the decrease of IL-1ß, IL-6, TNF-α, active caspase-3 and cytochrome c level. Our results suggest that Carnosine may provide neuroprotective effect after experimental ICH in rat models.


Asunto(s)
Apoptosis/fisiología , Encéfalo/metabolismo , Carnosina/uso terapéutico , Hemorragia Cerebral/tratamiento farmacológico , Hemorragia Cerebral/metabolismo , Estrés Oxidativo/fisiología , Animales , Apoptosis/efectos de los fármacos , Encéfalo/efectos de los fármacos , Carnosina/farmacología , Masculino , Estrés Oxidativo/efectos de los fármacos , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley
17.
Neurochem Res ; 42(4): 997-1005, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27995497

RESUMEN

Chemotherapy has always been one of the most effective ways in combating human glioma. However, the high metastatic potential and resistance toward standard chemotherapy severely hindered the chemotherapy outcomes. Hence, searching effective chemotherapy drugs and clarifying its mechanism are of great significance. Salinomycin an antibiotic shows novel anticancer potential against several human tumors, including human glioma, but its mechanism against human glioma cells has not been fully elucidated. In the present study, we demonstrated that salinomycin treatment time- and dose-dependently inhibited U251 and U87 cells growth. Mechanically, salinomycin-induced cell growth inhibition against human glioma was mainly achieved by induction of G1-phase arrest via triggering reactive oxide species (ROS)-mediated DNA damage, as convinced by the activation of histone, p53, p21 and p27. Furthermore, inhibition of ROS accumulation effectively attenuated salinomycin-induced DNA damage and G1 cell cycle arrest, and eventually reversed salinomycin-induced cytotoxicity. Importantly, salinomycin treatment also significantly inhibited the U251 tumor xenograft growth in vivo through triggering DNA damage-mediated cell cycle arrest with involvement of inhibiting cell proliferation and angiogenesis. The results above validated the potential of salinomycin-based chemotherapy against human glioma.


Asunto(s)
Daño del ADN/efectos de los fármacos , Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos , Glioma/metabolismo , Piranos/farmacología , Especies Reactivas de Oxígeno/metabolismo , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Daño del ADN/fisiología , Relación Dosis-Respuesta a Droga , Puntos de Control de la Fase G1 del Ciclo Celular/fisiología , Glioma/tratamiento farmacológico , Glioma/patología , Humanos , Masculino , Ratones , Ratones Desnudos , Piranos/uso terapéutico , Ensayos Antitumor por Modelo de Xenoinjerto/métodos
18.
Cell Mol Neurobiol ; 36(5): 647-55, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26224360

RESUMEN

Hypothermia treatment is one of the neuroprotective strategies that improve neurological outcomes effectively after brain damage. Minimally invasive surgery (MIS) has been an important treatment of intracerebral hemorrhage (ICH). Herein, we evaluated the neuroprotective effect and mechanism of MIS joint local cooling lavage (LCL) treatment on ICH via detecting the inflammatory responses, oxidative injury, and neuronal apoptosis around the hematoma cavity in rats. ICH model was established by type IV collagenase caudatum infusion. The rats were treated with MIS 6 h after injection, and then were lavaged by normothermic (37 °C) and hypothermic (33 °C) normal saline in brain separately. The results indicated that MIS joint LCL treatment showed enhanced therapeutic effects against ICH-induced inflammation injury and apoptosis in rats, as convinced by the decline of TUNEL-positive cells, followed by the decrease of IL-1ß and LDH and increase of IL-10 and SOD. This study demonstrated that the strategy of using MIS joint LCL may achieve enhanced neuroprotection against ICH-induced inflammation injury and apoptosis in rats with potential clinic application.


Asunto(s)
Apoptosis/efectos de los fármacos , Edema Encefálico/cirugía , Hemorragia Cerebral/complicaciones , Procedimientos Quirúrgicos Mínimamente Invasivos , Animales , Lesiones Encefálicas/cirugía , Hemorragia Cerebral/terapia , Inflamación/cirugía , Masculino , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Neuronas/metabolismo , Ratas Sprague-Dawley , Recuperación de la Función/fisiología , Irrigación Terapéutica/métodos
19.
Neurochem Res ; 41(6): 1439-47, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26846141

RESUMEN

Selenocysteine (SeC) a natural available selenoamino acid exhibits novel anticancer activities against human cancer cell lines. However, the growth inhibitory effect and mechanism of SeC in human glioma cells remain unclear. The present study reveals that SeC time- and dose-dependently inhibited U251 and U87 human glioma cells growth by induction of S-phase cell cycle arrest, followed by the marked decrease of cyclin A. SeC-induced S-phase arrest was achieved by inducing DNA damage through triggering generation of reactive oxygen species (ROS) and superoxide anion, with concomitant increase of TUNEL-positive cells and induction of p21waf1/Cip1 and p53. SeC treatment also caused the activation of p38MAPK, JNK and ERK, and inactivation of AKT. Four inhibitors of MAPKs and AKT pathways further confirmed their roles in SeC-induced S-phase arrest in human glioma cells. Our findings advance the understanding on the molecular mechanisms of SeC in human glioma management.


Asunto(s)
Puntos de Control del Ciclo Celular/fisiología , Daño del ADN/fisiología , Glioma/metabolismo , Sistema de Señalización de MAP Quinasas/fisiología , Proteína Oncogénica v-akt/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Selenocisteína/farmacología , Antineoplásicos/farmacología , Puntos de Control del Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Humanos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Selenio/farmacología
20.
Cell Biol Toxicol ; 32(4): 333-45, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27184666

RESUMEN

Caudatin as one species of C-21 steroidal from Cynanchum bungei decne displays potential anticancer activity. However, the underlying mechanisms remain elusive. In the present study, the growth suppressive effect and mechanism of caudatin on human glioma U251 and U87 cells were evaluated in vitro. The results indicated that caudatin significantly inhibited U251 and U87 cell growth in both a time- and dose-dependent manner. Flow cytometry analysis revealed that caudatin-induced cell growth inhibition was achieved by induction of cell apoptosis, as convinced by the increase of Sub-G1 peak, PARP cleavage and activation of caspase-3, caspase-7 and caspase-9. Caudatin treatment also resulted in mitochondrial dysfunction which correlated with an imbalance of Bcl-2 family members. Further investigation revealed that caudatin triggered U251 cell apoptosis by inducing reactive oxygen species (ROS) generation through disturbing the redox homeostasis. Moreover, pretreatment of caspase inhibitors apparently weakens caudatin-induced cell killing, PARP cleavage and caspase activation and eventually reverses caudatin-mediated apoptosis. Importantly, caudatin significantly inhibited U251 tumour xenografts in vivo through induction of cell apoptosis involving the inhibition of cell proliferation and angiogenesis, which further validate its value in combating human glioma in vivo. Taken together, the results described above all suggest that caudatin inhibited human glioma cell growth by induction of caspase-dependent apoptosis with involvement of mitochondrial dysfunction and ROS generation.


Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Caspasas/metabolismo , Glioma/tratamiento farmacológico , Glicósidos/farmacología , Especies Reactivas de Oxígeno/metabolismo , Esteroides/farmacología , Apoptosis/efectos de los fármacos , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patología , Inhibidores de Caspasas/farmacología , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Glioma/metabolismo , Glioma/patología , Humanos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA